Solana (HSDT) Projected to Post Earnings on Thursday

Solana (NASDAQ:HSDT) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $3.50 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Solana (NASDAQ:HSDT) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.96). Solana had a negative net margin of 1,427.15% and a negative return on equity of 67.57%. The company had revenue of $3.62 million during the quarter, compared to analysts’ expectations of $3.40 million. On average, analysts expect Solana to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Solana Price Performance

NASDAQ HSDT opened at $1.74 on Wednesday. The stock has a market capitalization of $101.60 million, a P/E ratio of -0.02 and a beta of 1.01. The firm’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.97. Solana has a 12 month low of $1.19 and a 12 month high of $25.50.

Analysts Set New Price Targets

HSDT has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a report on Friday, July 17th. B. Riley Financial assumed coverage on Solana in a research note on Thursday, April 23rd. They set a “buy” rating and a $3.00 price target on the stock. Finally, Zacks Research raised Solana to a “hold” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Solana in the fourth quarter valued at approximately $46,000. OMERS ADMINISTRATION Corp acquired a new stake in Solana during the 4th quarter worth approximately $88,000. Aristides Capital LLC acquired a new stake in Solana during the 4th quarter worth approximately $137,000. XTX Topco Ltd purchased a new position in Solana in the 4th quarter valued at approximately $140,000. Finally, Marshall Wace LLP purchased a new position in Solana in the 4th quarter valued at approximately $195,000. Hedge funds and other institutional investors own 18.63% of the company’s stock.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.